-
Sector Analysis
NewInternet from Sky – Can LEO Satellites Transform the Future of Connectivity? (Vol. 2)
LEO Satellites - Internet from Sky Report Overview The surge in low earth orbit (LEO) satellite projects indicates a global trend toward diversifying internet coverage. This trend focuses on bridging the digital divide and enhancing real-time data transmission for various sectors, including aerospace and defense. LEOs provide a competitive edge due to their lower latency, and their increasing deployment signifies a pivotal shift toward a more connected future. LEOs are more secure than terrestrial networks as communication happens in space...
-
Thematic Analysis
NewWeb3 – Thematic Intelligence
Web3 Thematic Report Overview Web3 is an ideology that refers to the next model of the internet built on blockchain. It promises a mix of peer-to-peer (P2P) communication channels and decentralized governance. This will lead the internet’s transition from an information-centric model to a user-centric model. Furthermore, Web3 aims to give users the ability to create, own, and monetize their content and manage the use of their data. However, it is still an emerging model and has a long way...
-
Innovation Ranking
Innovation Ranking – Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on gene therapies for rare and devastating diseases. The company has three clinical-stage ex vivo lentiviral vector (“LVV”) programs which include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces the production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction, and Pyruvate...
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPL-301
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPL-301 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Volrustomig
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Volrustomig report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPA-601
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPA-601 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s Mozafancogene Autotemcel
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's Mozafancogene Autotemcel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s Ladilen
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's Ladilen report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPA-501
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPA-501 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.